| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8911786 | AADI | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Feb, 2029
(5 years from now) | |
| US10206887 | AADI | Prion free nanoparticle compositions and methods of making thereof |
Apr, 2030
(6 years from now) | |
| US10705070 | AADI | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
Mar, 2036
(12 years from now) | |
| US10973806 | AADI | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Jun, 2036
(12 years from now) | |
| US11497737 | AADI | NA |
Oct, 2040
(17 years from now) | |
Fyarro is owned by Aadi.
Fyarro contains Sirolimus.
Fyarro has a total of 5 drug patents out of which 0 drug patents have expired.
Fyarro was authorised for market use on 22 November, 2021.
Fyarro is available in powder;intravenous dosage forms.
Fyarro can be used as treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma), treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle.
The generics of Fyarro are possible to be released after 28 October, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Nov 22, 2024 |
| Orphan Drug Exclusivity (ODE) | Nov 22, 2028 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or m...
Dosage: POWDER;INTRAVENOUS
FYARRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic